PGK1 has been identified as an independent prognostic marker for chemoresistance to paclitaxel treatment in patients with breast cancer, and patients with elevated PGK1 levels who are receiving paclitaxel chemotherapy have significantly shorter survival [62]. The gene discussed is PGK1; the disease is breast carcinoma.